Neurotech International (NTI) has updated the ASX on the development of its proprietary formulation for the treatment of multiple sclerosis (MS).

NTI said results from an in-vitro study conducted in conjunction with Melbourne’s RMIT University showed its NTI/Dolce Strains suppressed the production of two key inflammatory neuro-markers involved in MS by 40% and 30% respectively. CBD alone had no significant effect.

NTI said it is committed to the development of a solid scientific portfolio to expand the application and use of the strains beyond autism. Further preclinical studies will inform the design of a Phase I/II clinical study in MS.

Company chairman Brian Leedman said: “There are a number of very powerful neuro-markers that are currently being used to assess disease onset and progression. To be able to suppress or regulate these markers may be very beneficial in overall disease management.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...